Making A Federal Case Of Marketing Abuses: FDA Trains OCI Staff On Developing Cases Worth Prosecuting
Executive Summary
FDA is training investigators in its Office of Criminal Investigations on how to pursue cases against individuals for off-label drug promotion so that they are able to convince U.S. Attorneys' Offices to prosecute them.
You may also be interested in...
Rx Fraud Cases: Beat Goes On As Whistleblowers Pursue Lesser Allegations
“There are enough layoffs out there that there is this walking group of disaffected people who are continuing to file qui tams, whether those are valid or not,” Boston Assistant U.S. Attorney Susan Winkler says. A Pfizer attorney suggests proactive steps to protect corporate leaders from prosecution.
"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct
Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.
"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct
Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.